Should I buy or sell Monopar Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNPR shares. View MNPR analyst ratings or view top-rated stocks .

What is Monopar Therapeutics' stock price target for 2024?

1 analysts have issued 12 month target prices for Monopar Therapeutics' shares. Their MNPR share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 212.5% from the stock's current price. View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts .

How have MNPR shares performed in 2024?

Monopar Therapeutics' stock was trading at $0.3402 at the start of the year. Since then, MNPR shares have increased by 88.2% and is now trading at $0.6401. View the best growth stocks for 2024 here .

Are investors shorting Monopar Therapeutics?

Monopar Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 170,500 shares, a decrease of 25.7% from the March 15th total of 229,600 shares. Based on an average daily trading volume, of 5,230,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 2.3% of the shares of the stock are short sold. View Monopar Therapeutics' Short Interest .

When is Monopar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MNPR earnings forecast .

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX) , Fulcrum Therapeutics (FULC) , Sorrento Therapeutics (SRNE) , Akero Therapeutics (AKRO) , Chimerix (CMRX) , Trevena (TRVN) , Aldeyra Therapeutics (ALDX) , Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST) .

When did Monopar Therapeutics IPO?

Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Monopar Therapeutics have any subsidiaries?

The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. Read More

NASDAQ:MNPR

Monopar Therapeutics (MNPR) Stock Price, News & Analysis

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Free MNPR Stock Alerts

$0.64

-0.04 (-5.88%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.62
▼
$0.68
50-Day Range: $0.33
▼
$1.35
52-Week Range: $0.27
▼
$1.75

Volume: 33,081 shs
Average Volume: 4.50 million shs
Market Capitalization: $11.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Get Monopar Therapeutics alerts:

Monopar Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 212.5% Upside
$2.00 Price Target
Short Interest: Healthy
2.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.57
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.67) to ($0.62) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

402nd out of 911 stocks

Pharmaceutical Preparations Industry

177th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Monopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Monopar Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.29% of the float of Monopar Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Monopar Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Monopar Therapeutics has recently decreased by 25.74%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Monopar Therapeutics does not currently pay a dividend.
Dividend Growth
Monopar Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNPR.

2.0

News and Social Media Coverage

News Sentiment
Monopar Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Monopar Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.60% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.83% of the stock of Monopar Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Monopar Therapeutics are expected to grow in the coming year, from ($0.67) to ($0.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Monopar Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Monopar Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Monopar Therapeutics has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Porter & Company

New York goes dark, then America.

Artificial intelligence is about to trigger a shocking new crisis in New York. Experts warn it could be “the next 9/11” and while New York will be ground zero for this looming catastrophe, it will not be the only state impacted. This crisis could affect 233 million Americans starting at any moment from now.

Click here for the full story.

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

MNPR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MNPR Stock News Headlines

April 18, 2024 | globenewswire.com

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

April 16, 2024 | msn.com

Monopar files patent protecting its MNPR-101 radiopharma optimization findings

April 19, 2024 | Paradigm Press (Ad)

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

April 16, 2024 | finance.yahoo.com

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

April 13, 2024 | americanbankingnews.com

Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Jonestrading

April 11, 2024 | markets.businessinsider.com

Buy Rating on Monopar Therapeutics: Promising Trials and Financial Stability Highlight Growth Potential

April 10, 2024 | globenewswire.com

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

March 28, 2024 | finance.yahoo.com

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

April 19, 2024 | Paradigm Press (Ad)

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

March 28, 2024 | globenewswire.com

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

March 6, 2024 | marketwatch.com

Monpar Therapeutics Shares Rise 12% After Positive Preclinical Data for MNPR-101

March 5, 2024 | markets.businessinsider.com

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

March 5, 2024 | globenewswire.com

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

February 27, 2024 | globenewswire.com

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

February 24, 2024 | cnn.com

Monopar Therapeutics Inc

February 23, 2024 | markets.businessinsider.com

Dow Surges Over 150 Points; AerCap Posts Upbeat Earnings

February 22, 2024 | msn.com

What's Going On With Cancer-Focused Monopar Therapeutics Stock Today?

February 22, 2024 | msn.com

Monopar stock jumps 60% amid preclinical data for MNPR-101

February 22, 2024 | finance.yahoo.com

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

February 20, 2024 | benzinga.com

Crude Oil Moves Lower; Summit Therapeutics Shares Plummet

February 20, 2024 | marketwatch.com

Monopar Therapeutics Shares Surge on Australia Antibody-Trial Clearance

February 20, 2024 | msn.com

Why Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?

February 20, 2024 | finance.yahoo.com

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

February 20, 2024 | globenewswire.com

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

February 10, 2024 | reuters.com

Kyverna Therapeutics Inc

January 7, 2024 | finance.yahoo.com

Monopar Therapeutics Inc. (MNPR)

November 9, 2023 | finance.yahoo.com

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

See More Headlines

Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MNPR
CUSIP: N/A
CIK: 1645469
Web: www.monopartx.com
Phone: 847-388-0349
Fax: N/A
Employees: 11
Year Founded: 2014

Price Target and Rating

Average Stock Price Target: $2.00
High Stock Price Target: $2.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +209.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,400,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -115.79%
Return on Assets: -88.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.17
Quick Ratio: 4.17

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.38 per share
Price / Book: 1.70

Miscellaneous

Outstanding Shares: 17,450,000
Free Float: 10,194,000
Market Cap: $11.26 million
Optionable: Not Optionable
Beta: 1.19

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Chandler D. Robinson M.B.A. (Age 40)
M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director
Comp: $708.12k
Ms. Kim R. Tsuchimoto CPA (Age 61)
CFO, Secretary, Treasurer & Director
Comp: $350.55k
Mr. Andrew J. Cittadine M.B.A. (Age 52)
Chief Operating Officer
Comp: $390.41k
Dr. Patrice P. Rioux M.D. (Age 73)
Ph.D., Acting Chief Medical Officer

Key Competitors

View All Competitors

MNPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNPR shares.
View MNPR analyst ratings or view top-rated stocks.
What is Monopar Therapeutics' stock price target for 2024?: 1 analysts have issued 12 month target prices for Monopar Therapeutics' shares. Their MNPR share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 212.5% from the stock's current price.
View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts.
How have MNPR shares performed in 2024?: Monopar Therapeutics' stock was trading at $0.3402 at the start of the year. Since then, MNPR shares have increased by 88.2% and is now trading at $0.6401.
View the best growth stocks for 2024 here.
Are investors shorting Monopar Therapeutics?: Monopar Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 170,500 shares, a decrease of 25.7% from the March 15th total of 229,600 shares. Based on an average daily trading volume, of 5,230,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 2.3% of the shares of the stock are short sold.
View Monopar Therapeutics' Short Interest.
When is Monopar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MNPR earnings forecast.
How were Monopar Therapeutics' earnings last quarter?: Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02.

What other stocks do shareholders of Monopar Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).
When did Monopar Therapeutics IPO?: Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.
How do I buy shares of Monopar Therapeutics?: Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Monopar Therapeutics have any subsidiaries?: The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.
Read More

This page (NASDAQ:MNPR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial